Innovation Pharmaceuticals Inc. IPIX

Company Overview

Innovation Pharmaceuticals Inc. (traded over-the-counter under the symbol IPIX and formerly known as Cellceutix Corporation) is a clinical-stage biopharmaceutical company focused on the development of therapies for inflammatory diseases, infectious diseases, and oncology-related indications. The company’s operations have historically centered on small-molecule drug candidates, with a strategic emphasis on host-directed therapies and anti-inflammatory compounds. Its lead development programs have included brilanestrant-related oncology research in earlier years and, more recently, the anti-inflammatory peptide mimetic candidate brilacidin for infectious and gastrointestinal conditions.

The company primarily operates in the biotechnology and pharmaceutical development sector and does not currently generate material commercial product revenue based on publicly available filings. Instead, its business model has relied on capital raising, licensing discussions, research collaborations, and clinical development activities. Innovation Pharmaceuticals evolved from a broader oncology-focused development company into a more concentrated clinical research organization emphasizing brilacidin applications in inflammatory bowel disease, oral mucositis, and infectious disease indications. Public disclosures indicate the company has sought to position itself around the potential broad applicability of defensin-mimetic compounds and anti-inflammatory therapeutics.